Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.29
- Piotroski Score 7.00
- Grade Outperform
- Symbol (SIGA)
- Company SIGA Technologies, Inc.
- Price $7.63
- Changes Percentage (-1.17%)
- Change -$0.09
- Day Low $7.60
- Day High $7.97
- Year High $12.83
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
- Last Earnings 03/12/2024
- Ex-Dividend for 5/16 Dividend 03/25/2024
- Dividend Payable 04/11/2024
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.10
- Trailing P/E Ratio 6.98
- Forward P/E Ratio 6.98
- P/E Growth 6.98
- Net Income $68.07 M
Income Statement
Quarterly
Annual
Latest News of SIGA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NYC's ex-COVID czar's media 'spin' comments on SIGA technologies...
An investigation is underway into potential securities law violations by SIGA Technologies, involving former exec Dr. Jay Varma. Varma admitted to spinning media stories about the company's monkeypox ...
By New York Post | 1 month ago -
Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst
SIGA Technologies secured a $9 million contract with the U.S. Department of Defense for TPOXX. The company also received $27 million for developing post-exposure Prophylaxis indication. Edison report ...
By Yahoo! Finance | 2 months ago
